PriceTargets.com logo

Biomea Fusion - BMEA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $30.50
  • Forecasted Upside: 385.67%
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 8 Buy Ratings
  • 2 Strong Buy Ratings
$6.28 As of 11/20/2024 01:00 AM ET
▼ -0.14 (-2.18%)

This chart shows the closing price for BMEA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Biomea Fusion Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BMEA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BMEA

Analyst Price Target is $30.50
▲ +385.67% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Biomea Fusion in the last 3 months. The average price target is $30.50, with a high forecast of $60.00 and a low forecast of $11.00. The average price target represents a 385.67% upside from the last price of $6.28.

This chart shows the closing price for BMEA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 12 investment analysts is to buy stock in Biomea Fusion. This rating has held steady since September 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 2 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 2 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 2 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/31/2024Piper SandlerBoost TargetOverweight ➝ Overweight$10.00 ➝ $19.00
10/31/2024HC WainwrightReiterated RatingBuy ➝ Buy$40.00 ➝ $40.00
10/30/2024BarclaysBoost TargetEqual Weight ➝ Equal Weight$9.00 ➝ $11.00
10/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$40.00 ➝ $40.00
10/9/2024EF Hutton Acquisition Co. IUpgradeStrong-Buy
9/27/2024ScotiabankBoost TargetSector Outperform ➝ Sector Outperform$21.00 ➝ $41.00
9/27/2024HC WainwrightBoost TargetBuy ➝ Buy$15.00 ➝ $40.00
9/27/2024BarclaysBoost TargetEqual Weight ➝ Equal Weight$5.00 ➝ $9.00
9/27/2024Truist FinancialUpgradeHold ➝ Buy$54.00 ➝ $54.00
9/26/2024RODMAN&RENSHAWUpgradeStrong-Buy
9/26/2024Rodman & RenshawUpgradeNeutral ➝ Buy$18.00
8/29/2024Capital One FinancialInitiated CoverageOverweight$25.00
8/27/2024CitigroupLower TargetBuy ➝ Buy$45.00 ➝ $22.00
8/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
6/25/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
6/11/2024Truist FinancialDowngradeBuy ➝ Hold
6/7/2024CitigroupLower TargetBuy ➝ Buy$90.00 ➝ $45.00
6/7/2024HC WainwrightLower TargetBuy ➝ Buy$50.00 ➝ $15.00
6/7/2024Piper SandlerLower TargetOverweight ➝ Overweight$45.00 ➝ $10.00
6/7/2024ScotiabankLower TargetSector Outperform ➝ Sector Outperform$41.00 ➝ $21.00
6/7/2024BarclaysDowngradeOverweight ➝ Equal Weight$30.00 ➝ $5.00
5/30/2024OppenheimerLower TargetOutperform ➝ Outperform$70.00 ➝ $60.00
5/3/2024HC WainwrightReiterated RatingBuy ➝ Buy$50.00
5/3/2024JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$14.00 ➝ $15.00
4/3/2024OppenheimerReiterated RatingOutperform ➝ Outperform$70.00
4/2/2024JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Neutral$51.00 ➝ $14.00
4/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$50.00
4/1/2024Truist FinancialReiterated RatingBuy ➝ Buy$55.00
3/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$50.00
2/6/2024Truist FinancialInitiated CoverageBuy$55.00
12/8/2023CitigroupReiterated RatingBuy ➝ Buy$90.00
8/1/2023HC WainwrightReiterated RatingBuy ➝ Buy$50.00
7/27/2023ScotiabankInitiated CoverageOutperform$41.00
7/24/2023HC WainwrightReiterated RatingBuy ➝ Buy$50.00
6/26/2023Jefferies Financial GroupDowngradeBuy ➝ Hold
6/26/2023Piper SandlerBoost Target$40.00 ➝ $45.00
6/26/2023HC WainwrightBoost Target$37.00 ➝ $50.00
6/26/2023BarclaysBoost Target$50.00 ➝ $60.00
5/18/2023CitigroupLower Target$55.00 ➝ $53.00
5/12/2023BarclaysInitiated CoverageOverweight$50.00
4/19/2023HC WainwrightLower TargetBuy$44.00 ➝ $37.00
4/11/2023OppenheimerReiterated RatingOutperform$47.00
4/7/2023CitigroupLower Target$60.00 ➝ $55.00
4/6/2023EF Hutton Acquisition Co. IReiterated RatingBuy$33.00
3/29/2023OppenheimerBoost TargetOutperform$25.00 ➝ $47.00
3/29/2023CitigroupBoost TargetBuy$20.00 ➝ $60.00
3/28/2023EF Hutton Acquisition Co. IBoost TargetBuy$22.00 ➝ $33.00
3/28/2023HC WainwrightBoost TargetBuy$37.00 ➝ $44.00
3/28/2023Piper SandlerBoost TargetOverweight$16.00 ➝ $40.00
3/24/2023Keefe, Bruyette & WoodsReiterated RatingBuy$22.00
3/21/2023EF Hutton Acquisition Co. IReiterated RatingBuy$22.00
2/24/2023CitigroupInitiated CoverageBuy$20.00
1/13/2023HC WainwrightReiterated RatingBuy$37.00
12/16/2022HC WainwrightReiterated RatingBuy$37.00
11/8/2022EF Hutton Acquisition Co. ILower TargetBuy$27.00 ➝ $22.00
11/1/2022EF Hutton Acquisition Co. IInitiated CoverageBuy$27.00
10/31/2022HC WainwrightBoost TargetBuy$16.00 ➝ $37.00
8/2/2022HC WainwrightReiterated RatingBuy$16.00
6/2/2022HC WainwrightReiterated RatingBuy$16.00
5/27/2022Piper SandlerLower Target$25.00 ➝ $16.00
5/17/2022Piper SandlerLower Target$27.00 ➝ $25.00
1/12/2022HC WainwrightInitiated CoverageBuy$13.00
12/16/2021OppenheimerInitiated CoverageOutperform
5/11/2021JPMorgan Chase & Co.Initiated CoverageOverweight$26.00
5/11/2021Piper SandlerInitiated CoverageOverweight$27.00
5/11/2021Jefferies Financial GroupInitiated CoverageBuy$26.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.31 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2024
  • 4 very positive mentions
  • 10 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 0 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 4 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 2 very positive mentions
  • 10 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 6 very positive mentions
  • 23 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 2 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 2 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Biomea Fusion logo
Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Read More

Today's Range

Now: $6.28
Low: $6.04
High: $6.55

50 Day Range

MA: $9.45
Low: $6.28
High: $12.41

52 Week Range

Now: $6.28
Low: $3.61
High: $22.74

Volume

552,219 shs

Average Volume

1,006,515 shs

Market Capitalization

$227.58 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Biomea Fusion?

The following equities research analysts have issued reports on Biomea Fusion in the last year: Barclays PLC, Capital One Financial Co., Citigroup Inc., EF Hutton Acquisition Co. I, HC Wainwright, JPMorgan Chase & Co., Oppenheimer Holdings Inc., Piper Sandler, Rodman & Renshaw, RODMAN&RENSHAW, Scotiabank, and Truist Financial Co..
View the latest analyst ratings for BMEA.

What is the current price target for Biomea Fusion?

0 Wall Street analysts have set twelve-month price targets for Biomea Fusion in the last year. Their average twelve-month price target is $30.50, suggesting a possible upside of 385.7%. Oppenheimer Holdings Inc. has the highest price target set, predicting BMEA will reach $60.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $11.00 for Biomea Fusion in the next year.
View the latest price targets for BMEA.

What is the current consensus analyst rating for Biomea Fusion?

Biomea Fusion currently has 2 hold ratings, 8 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BMEA will outperform the market and that investors should add to their positions of Biomea Fusion.
View the latest ratings for BMEA.

What other companies compete with Biomea Fusion?

Other companies that are similar to Biomea Fusion include Chiasma, Epizyme, Acumen Pharmaceuticals, Paratek Pharmaceuticals and Ovid Therapeutics. Learn More about companies similar to Biomea Fusion.

How do I contact Biomea Fusion's investor relations team?

The company's listed phone number is 650-980-9099 and its investor relations email address is [email protected]. The official website for Biomea Fusion is www.biomeafusion.com. Learn More about contacing Biomea Fusion investor relations.